| Product Code: ETC7181755 | Publication Date: Sep 2024 | Updated Date: Oct 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 | |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Overview |
3.1 Fiji Country Macro Economic Indicators |
3.2 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, 2021 & 2031F |
3.3 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market - Industry Life Cycle |
3.4 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market - Porter's Five Forces |
3.5 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.6 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume Share, By Manufacturer Type, 2021 & 2031F |
3.7 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume Share, By Type of Synthesis, 2021 & 2031F |
3.8 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume Share, By Indication, 2021 & 2031F |
4 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer cases in Fiji |
4.2.2 Growing awareness about the importance of early detection and treatment of cancer |
4.2.3 Government initiatives to improve healthcare infrastructure and services in Fiji |
4.3 Market Restraints |
4.3.1 High cost associated with oncology APIs |
4.3.2 Limited access to advanced oncology treatments in remote areas of Fiji |
4.3.3 Stringent regulatory requirements for the approval of oncology APIs |
5 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Trends |
6 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market, By Types |
6.1 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market, By Drug Type |
6.1.1 Overview and Analysis |
6.1.2 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Drug Type, 2021- 2031F |
6.1.3 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Innovative Oncology APIs, 2021- 2031F |
6.1.4 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Generic Oncology APIs, 2021- 2031F |
6.2 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market, By Manufacturer Type |
6.2.1 Overview and Analysis |
6.2.2 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Captive Manufacturers, 2021- 2031F |
6.2.3 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Merchant Manufacturers, 2021- 2031F |
6.3 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market, By Type of Synthesis |
6.3.1 Overview and Analysis |
6.3.2 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Synthetic Oncology APIs, 2021- 2031F |
6.3.3 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Biotech Oncology APIs, 2021- 2031F |
6.4 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market, By Indication |
6.4.1 Overview and Analysis |
6.4.2 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Lung Cancer, 2021- 2031F |
6.4.3 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Breast Cancer, 2021- 2031F |
6.4.4 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Colorectal Cancer, 2021- 2031F |
6.4.5 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Prostate Cancer, 2021- 2031F |
6.4.6 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Stomach Cancer, 2021- 2031F |
6.4.7 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Liver Cancer, 2021- 2031F |
6.4.8 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Others, 2021- 2031F |
6.4.9 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Others, 2021- 2031F |
7 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Import-Export Trade Statistics |
7.1 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Export to Major Countries |
7.2 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Imports from Major Countries |
8 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Key Performance Indicators |
8.1 Number of oncology API research and development partnerships in Fiji |
8.2 Percentage of oncology APIs meeting quality standards and regulatory requirements in Fiji |
8.3 Rate of adoption of new and innovative oncology APIs in Fiji |
9 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market - Opportunity Assessment |
9.1 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.2 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Opportunity Assessment, By Manufacturer Type, 2021 & 2031F |
9.3 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Opportunity Assessment, By Type of Synthesis, 2021 & 2031F |
9.4 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Opportunity Assessment, By Indication, 2021 & 2031F |
10 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market - Competitive Landscape |
10.1 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Revenue Share, By Companies, 2024 |
10.2 Fiji Oncology Active Pharmaceutical Ingredients (APIs) Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |